I am a medical oncologist with special interest and expertise in treating patients who have upper gastrointestinal cancers, particularly those with esophageal cancer. My research focus is studying new agents to treat advanced disease and evaluating novel agents in combined-modality therapy to treat locally advanced disease.
In 1992, I joined Memorial Sloan Kettering Cancer Center’s Gastrointestinal Oncology Service. I am an attending physician and member at Memorial Hospital and a professor of medicine at Weill Cornell Medical College. I completed a fellowship in medical oncology and hematology here at Memorial Sloan Kettering after receiving master’s and PhD degrees in basic science and an MD degree from New York University. I completed my internship and residency in internal medicine at Bellevue Hospital at NYU Medical Center. My undergraduate training was at the University of Connecticut.
I am a member of the GI committees of the national clinical research groups Cancer and Leukemia Group B (CALGB) and Radiation Therapy Oncology Group (RTOG). I am also a member of the Upper GI Cancer Guidelines Committee of National Comprehensive Cancer Network (NCCN) and chairman of the Intergroup Esophageal and Gastric Cancer Task Force Committee.
- Clinical Expertise: Colorectal, Esophageal, Pancreatic, Gastric, and Other Gastrointestinal Cancers; Unknown Primary Tumors
- Awards and Honors: New York Magazine Top Doctors (2007-2009; 2016)
- Languages Spoken: English
- Education: MD, PhD, New York University School of Medicine
- Residencies: NYU Medical Center/Bellevue Hospital
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by David H. Ilson
- A Phase II Study of Afatinib (BIBW 2992) in Patients with Advanced HER2-Positive Esophagogastric Cancer Refractory to Trastuzumab
- A Phase II Study of Nintedanib in Patients with Advanced Esophagogastric Cancer
- A Phase II Study of Pembrolizumab Immunotherapy plus Standard Therapy for Metastatic HER2-Positive Esophagogastric Cancer
- A Phase II Study of Ramucirumab plus Chemotherapy in Patients with Metastatic Gastric and Gastroesophageal Junction Cancers
- A Phase III Study of TAS-102 or Placebo with Best Supportive Care to Treat Persistent Metastatic Stomach Cancer
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more